Zevra Therapeutics Inc
KMPH
Market Cap$200.47M
Close$
$34.03
485.7% upside
Current Fair Value
485.7% upsideUndervalued by 485.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $200.47 Million |
|---|---|
| Enterprise Value | $196.96 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.2 |
| Beta | 2.16 |
| Outstanding Shares | 34,724,614 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4 |
|---|---|
| PEG | -3.57 |
| Price to Sales | - |
| Price to Book Ratio | 5.81 |
| Enterprise Value to Revenue | 11.89 |
| Enterprise Value to EBIT | -7.91 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About KemPharm Inc
22 employees
CEO: Travis Mickle KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...